A small-molecule “scavenger” that reduces inflammation and formation of atherosclerotic plaque in blood vessels in mice potentially could lead to a new approach for treating atherosclerosis in humans, according to researchers at Vanderbilt University Medical Center.
Sean Davies and colleagues are exploring lipid aldehydes produced during oxidative stress and their contribution to HDL dysfunction and atherosclerosis.
Imagine an inherited cause of early heart attacks that is more common than type-1 diabetes, multiple sclerosis or cystic fibrosis, but goes largely unrecognized.
In some cases, HDL, the “good cholesterol,” may not function properly and may actually accelerate atherosclerosis.
Accessibility Tools